The #2 cisplatin hit DHFR (Fig. 3b) is targeted by methotrexate, which is core therapy in osteosarcoma, combined in sequence with cisplatin40, and #4 ranked cisplatin hit CDC7 (Fig. 3b) is supported by existing in vitro results41. The gene discussed is DHFR; the disease is osteosarcoma.